A proposed OMB rule has raised concerns among scientists that U.S. research funding could be undermined through reduced reliance on peer review and expanded influence for political appointees. The rule also includes mechanisms that would make it easier for the government to terminate active grants. Coverage highlighted fears that the changes could reshape how federal agencies evaluate merit and continuity of funding, potentially affecting early-stage exploration and translational research pipelines. While the proposal is not yet law, it is already prompting debate across the research ecosystem. For biotech, the risk is indirect but material: disrupted academic and government-funded discovery can reverberate through target validation, preclinical tooling, and innovation capacity that sponsors eventually translate into programs.